PRA Health Sciences was a prominent global contract research organization (CRO) that provided a broad range of outsourced clinical development and data solution services to the pharmaceutical and biotechnology industries. Founded in 1982, PRA was dedicated to advancing clinical research through innovative approaches and a patient-centric focus. Their services spanned the entire lifecycle of drug development, from early phase studies to post-approval research, including clinical trial management, biostatistics, regulatory consulting, and data management. In July 2021, PRA Health Sciences was acquired by ICON plc in a landmark deal valued at approximately $12 billion, creating one of the world's largest and most comprehensive CROs.
Served as the global corporate and operational headquarters, housing executive leadership, strategic planning, finance, legal, human resources, and oversight of global clinical trial operations.
The headquarters was located in a modern office park, featuring facilities designed to support a large-scale, technology-driven CRO. It likely included collaborative workspaces and advanced IT infrastructure.
The work culture at PRA's HQ was typically described as innovative, patient-focused, and collaborative, with a strong emphasis on quality, scientific rigor, and meeting the complex needs of pharmaceutical and biotech clients.
The Raleigh headquarters was pivotal to PRA's global strategy and operations, coordinating research activities across numerous countries and establishing its reputation as a leading CRO.
Before being acquired by ICON, PRA Health Sciences had an extensive global reach, with operations in more than 90 countries across North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East. This widespread presence enabled the company to conduct large, complex, multinational clinical trials. Globally supported functions included clinical trial management and site monitoring, patient recruitment and retention, data management and biostatistics, regulatory affairs strategy and submissions, medical writing, pharmacovigilance, and bioanalytical laboratory services.
4130 Parklake Ave
Raleigh
North Carolina
USA
Address: 721 Arbor Way, Suite 100, Blue Bell, PA 19422, USA
Acted as a key hub for East Coast US operations, facilitating engagement with numerous biotech and pharmaceutical companies headquartered in the Pennsylvania/New Jersey/New York corridor.
Address: The Ethos Building, Kings Rd, Swansea SA1 8AS, United Kingdom
Supported PRA's extensive clinical trial activities throughout the UK and continental Europe, navigating diverse regulatory environments and patient populations.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, PRA Health Sciences' leadership includes:
PRA Health Sciences has been backed by several prominent investors over the years, including:
The acquisition of PRA Health Sciences by ICON plc, finalized in July 2021, was the primary driver of executive changes. PRA's leadership team largely transitioned out of their roles or took on new responsibilities within the combined ICON organization. In the 12 months leading up to the acquisition finalization, there were no major, distinct executive hires or departures publicly announced for PRA Health Sciences as an independent entity, as focus shifted towards the merger and integration.
Discover the tools PRA Health Sciences uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition by ICON plc, PRA Health Sciences utilized standard corporate email formats. The most common structures typically involved combinations of an employee's first name and last name, or initials, followed by the '@prahs.com' domain. These formats are now historical as the prahs.com domain is no longer in active use for email by the former entity.
[firstinitial][lastname]@prahs.com (e.g., jdoe@prahs.com) or [firstname].[lastname]@prahs.com (e.g., john.doe@prahs.com)
Format
jsmith@prahs.com
Example
80%
Success rate
ICON plc Newsroom • July 1, 2021
ICON plc (NASDAQ: ICLR) today announced that it has completed its acquisition of PRA Health Sciences, Inc. The combination brings together two of the highest quality, most innovative and fastest growing organisations in the sector, creating the world’s most advanced healthcare intelligence and clinical research organisation....more
Business Wire (for ICON plc) • February 24, 2021
ICON plc (NASDAQ: ICLR) and PRA Health Sciences, Inc. (NASDAQ: PRAH) today announced that they have entered into a definitive agreement under which ICON will acquire PRA in a cash and stock transaction valued at approximately $12 billion. The transaction brings together two high-quality, growing organizations with similar cultures and a shared focus on high quality and efficient clinical trial execution from Phase 1 to post-approval studies....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including PRA Health Sciences, are just a search away.